Share This

Public company info - China NT Pharma Group Co. Ltd. , 01011.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

China NT Pharma Group Co. Ltd., 01011.HK - Cash Flow 2020-12 2019-12 2018-12 2017-12 2016-12 2015-12 2014-12 2013-12 2012-12 2011-12 2010-12 2009-12 2008-12
Net Cash Flow from Operating Activities 26,154 48,973 -119,771 154,673 24,157 -95,855 90,390 -15,666 65,738 -191,933 -298,355 -233,505 -31,069
Net Cash Flow from Return on Investments & Servicing of Finance -62,539 -92,247 -116,340 -74,308 -38,220 -48,778 -71,548 -35,719 -52,672 -54,671 -45,560 -15,942 -12,555
　Interest Received 2,835 1,884 2,102 2,796 4,061 5,697 6,137 9,852 6,426 3,412 619 1,186 1,722
　Interest Paid -65,374 -94,131 -61,733 -43,150 -29,032 -54,475 -77,685 -45,571 -59,098 -58,083 -45,379 -17,128 -14,277
　Dividend Received 0 0 0 0 0 0 0 0 0 0 0 0 0
　Dividend Paid 0 0 -56,709 -33,954 -13,249 0 0 0 0 0 -800 0 0
　Others 0 0 0 0 0 0 0 0 0 0 0 0 0
Taxes (Paid) / Refunded 50 -1,208 -4,432 -7,112 -3,464 -1,543 -17,667 -22,814 -72,580 -57,092 -84,880 -17,769 -6,630
Net Cash Flow from Investing Activities 592,767 -208,759 -145,345 -246,887 -858,281 -85,866 79,334 -135,080 -65,462 -43,353 -58,218 -64,205 -68,567
　Additions to Fixed Assets -23,844 -36,034 -11,929 -9,734 -11,953 -37,996 -88,587 -8,324 -43,354 -23,407 -68,695 -63,619 -72,055
　Disposal of Fixed Assets 0 4 371 53,454 435 1,374 262 34,037 0 217 3,247 255 1,578
　Increase in Investments -1,029 -4,772 -2,000 -21,533 -21,513 -81,252 -3,000 0 0 0 0 0 0
　Decrease in Investments 558,370 0 0 0 0 0 0 0 0 0 0 0 0
　Net Cash Flow with Related Parties 0 0 0 0 0 50,000 0 0 -60,000 -24,627 98,206 151,664 157,651
　Others 59,270 -167,957 -131,787 -269,074 -825,250 -17,992 170,659 -160,793 37,892 4,464 -90,976 -152,505 -155,741
Net Cash Flow before Financing Activities 556,432 -253,241 -385,888 -173,634 -875,808 -232,042 80,509 -209,279 -124,976 -347,049 -487,013 -331,421 -118,821
Net Cash Flow from Financing Activities -558,871 195,504 337,457 225,991 626,045 212,853 34,804 194,537 -2,949 579,023 424,283 476,739 122,478
　New Loans 1,166,330 1,023,619 1,544,501 524,050 1,070,391 260,000 280,983 53,301 1,016,351 1,597,963 2,102,340 2,137,928 584,095
　Loans Repayment -1,729,132 -1,047,978 -1,198,257 -736,446 -319,112 -319,091 -366,179 -294,014 -1,016,434 -1,906,793 -1,776,263 -1,812,853 -619,268
　Fixed Income/Debt Instruments 13,481 241,916 0 0 0 0 120,000 288,250 237,080 0 0 0 0
　Repayment of Fixed Income/Debt Instruments -9,550 -21,007 0 0 -120,000 -320,000 0 0 0 0 0 0 0
　Equity Financing 0 0 0 470,241 270 553,248 0 0 54 933,786 0 0 0
　Net Cash Flow with Related Parties 0 0 0 0 0 50,000 0 0 -60,000 -24,627 98,206 151,664 157,651
　Others 0 -1,046 -8,787 -31,854 -5,504 -11,304 0 147,000 -180,000 -21,306 0 0 0
Increase(Decrease) in Cash & Cash Equivalents -2,439 -57,737 -48,431 52,357 -249,763 -19,189 115,313 -14,742 -127,925 231,974 -62,730 145,318 3,657
Cash & Cash Equivalents at Beginning of Year 28,198 87,793 146,868 89,624 327,995 346,062 229,239 246,030 373,755 149,810 212,240 66,934 64,884
Net Cash Flow due to Change in Exchange Rate/Others -17,923 -1,858 -10,644 4,887 11,392 1,122 1,510 -2,049 200 -8,029 300 -12 -1,607
Cash & Cash Equivalents at End of Year 7,836 28,198 87,793 146,868 89,624 327,995 346,062 229,239 246,030 373,755 149,810 212,240 66,934
Currency Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi Renminbi
Unit Thousand Thousand Thousand Thousand
Auditor's Opinion 1 1 1 1 1 1 1 2 2 1 0 0 0

Notes:1–Unqualified; 2–Unqualified ( not qualified in respect of fundamental uncertainly because of proper disclosure); 3–Qualified

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.